NCT03293030

Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 17 (actual)
• Sponsor: University of California, San Francisco · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a single-arm, open-label study to examine the effect of dupilumab on the immunologic and genetic environment within atopic dermatitis skin lesions.

Detailed description

Fifteen subjects with moderate to severe AD will receive dupilumab for a treatment period of 52 weeks (i.e. last injection on week 50). Biopsy samples from AD subjects and surgical discard samples will undergo molecular profiling. Skin swabs and stool samples will be collected and banked for future analysis. The reason to treat patients for 52 weeks is to have the ability to correlate early molecular events with clinical outcomes at week 52.

Conditions

• Atopic Dermatitis
• Atopic Dermatitis Eczema
• Eczema
• Atopic Dermatitis and Related Conditions

Interventions

Type	Name	Description
DRUG	Dupilumab	Dupilumab treatment

Timeline

• Start date: 2018-10-22
• Primary completion: 2023-02-23
• Completion: 2023-02-23
• First posted: 2017-09-26
• Last updated: 2025-11-14
• Results posted: 2025-11-14

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study